-
公开(公告)号：US11945807B2
公开(公告)日：2024-04-02
申请号：US17661909
申请日：2022-05-03
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC classification number: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20240327535A1
公开(公告)日：2024-10-03
申请号：US18741705
申请日：2024-06-12
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61P35/00 , A61K2039/505 , C07K2317/92
Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：US12043670B2
公开(公告)日：2024-07-23
申请号：US17339549
申请日：2021-06-04
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
CPC classification number: C07K16/2878 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/65 , A61K47/6803 , A61K47/6849 , A61P35/00 , A61K2039/505 , C07K2317/92
Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：US11998544B2
公开(公告)日：2024-06-04
申请号：US17059876
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , James Palacino , Michael Seiler , Ping Zhu , Evan Barry , Lihua Yu
IPC: A61K31/496 , A61K35/17 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/39 , A61K39/395 , A61K47/68
CPC classification number: A61K31/496 , A61K35/17 , A61K38/191 , A61K38/2013 , A61K38/2066 , A61K38/208 , A61K38/2086 , A61K38/217 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K47/6803 , A61K2039/6031 , A61K2039/6037 , A61K2039/6056 , A61K2039/6081
Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
-
公开(公告)号：US11926619B2
公开(公告)日：2024-03-12
申请号：US17045952
申请日：2019-04-08
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Gregg F. Keaney , John Wang , Baudouin Gerard , Kenzo Arai , Xiang Liu , Guo Zhu Zheng , Kazunobu Kira , Lisa A. Marcaurelle , Marta Nevalainen , Ming-Hong Hao , Morgan Welzel O'Shea , Parcharee Tivitmahaisoon , Sudeep Prajapati , Tuoping Luo , Nicholas C. Gearhart , Jason T. Lowe , Yoshihiko Kotake , Satoshi Nagao , Regina Mikie Kanada Sonobe , Masayuki Miyano , Norio Murai , Andrew Cook , Shelby Ellery , Atsushi Endo , James Palacino , Dominic Reynolds
IPC: C07D407/12 , A61K31/365 , A61K31/4427 , A61K31/497 , A61K45/06 , A61P35/00 , C07D313/00 , C07D405/12 , C07D405/14 , C07D407/06 , C07D407/14 , C07D413/12 , C07D417/12 , C07D487/08 , C07D487/10 , C07D491/107
CPC classification number: C07D407/06 , A61K45/06 , A61P35/00 , C07D313/00 , C07D405/12 , C07D405/14 , C07D413/12 , C07D417/12 , C07D487/08 , C07D487/10 , C07D491/107
Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
-
Patent Agency Ranking
公开(公告)号：US12172986B2
公开(公告)日：2024-12-24
申请号：US17059635
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US11679107B2
公开(公告)日：2023-06-20
申请号：US17046528
申请日：2019-04-11
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Andrew Cook , Dominic Reynolds , Cheng Zhong , Ryan Brawn , Shelby Ellery , Thiwanka Samarakoon , Xiang Liu , Sudeep Prajapati , Megan Sheehan , Jason T. Lowe , James Palacino
IPC: C07D405/06 , A61K31/496 , A61P35/00 , A61K9/00 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/395 , C07D313/00 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08
CPC classification number: A61K31/496 , A61K9/0053 , A61K31/497 , A61K31/506 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/551 , A61K38/191 , A61K38/208 , A61K38/2013 , A61K38/2066 , A61K38/2086 , A61K38/217 , A61K39/3955 , A61P35/00 , C07D313/00 , C07D405/06 , C07D405/10 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D453/02 , C07D471/10 , C07D487/04 , C07D491/107 , C07D498/08 , C07B2200/05
Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy
-
公开(公告)号：US11352348B2
公开(公告)日：2022-06-07
申请号：US17247117
申请日：2020-11-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira Pazolli , Silvia Buonamici , Thiwanka Samarakoon , Sudeep Prajapati , Nathan Fishkin , James Palacino , Michael Seiler , Ping Zhu , Andrew Cook , Peter Smith , Xiang Liu , Shelby Ellery , Dominic Reynolds , Lihua Yu , Zhenhua Wu , Shouyong Peng , Nicholas Calandra , Megan Sheehan , Yonghong Xiao
IPC: C07D405/12 , A61P35/00 , A61K47/68 , A61K47/60 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20220081486A1
公开(公告)日：2022-03-17
申请号：US17339549
申请日：2021-06-04
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Ryan Henry , Thiwanka Samarakoon , Nathan Fishkin , Ping Zhu , Ermira Pazolli , James Palacino , Juan C. Almagro
Abstract: Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates (ADCs) such as those comprising a splicing modulator) that bind to BCMA are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering a composition provided herein.
-
公开(公告)号：US20220031859A1
公开(公告)日：2022-02-03
申请号：US17312320
申请日：2019-12-12
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Nathan Fishkin , Thiwanka Samarakoon , James Palacino , Kenzo Arai , Yoshihiko Kotake , Shinya Okubo , Norio Murai , Masayuki Miyano
IPC: A61K47/68 , A61K47/60 , A61P35/00 , A61K39/395 , A61K39/00 , C12Q1/6886 , C07D407/06 , C07D405/14
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a herboxidiene splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. The herboxidiene itself is also claimed. Further claims are directed to its use, and to the use of a neoantigen, generated by the herboxidiene or its ADC, or a vaccine against this neoantigen.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.016 seconds)
